Nabriva, Austria

Drug development antibacterials


HBM contact: Dr Ivo Staijen, Dr Ulrich Geilinger

Company status: public

Nabriva Therapeutics is developing pleuromutilin antibiotics, a new class of antibacterial compounds, for the treatment of serious infections in humans caused by multi-drug resistant pathogens.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171